Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT02819999 |
Title | A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer |
Recruitment | Terminated |
Gender | both |
Phase | Phase I |
Variant Requirements | No |
Sponsors | Stemcentrx |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
University of Colorado | Aurora | Colorado | 80010 | United States | Details | |
Rocky Mountain Cancer Centers | Denver | Colorado | 80218 | United States | Details | |
Cancer Institute of Florida | Orlando | Florida | 32804 | United States | Details | |
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | Baltimore | Maryland | 21231 | United States | Details | |
Washington University | Saint Louis | Missouri | 63110 | United States | Details | |
Oncology Hematology Care | Cincinnati | Ohio | 45242 | United States | Details | |
University Hospital of Cleveland | Cleveland | Ohio | 44106 | United States | Details | |
Cleveland Clinic | Cleveland | Ohio | 44195 | United States | Details | |
University of Pittsburgh | Pittsburgh | Pennsylvania | 15232 | United States | Details | |
Texas Oncology | Fort Worth | Texas | 76104 | United States | Details | |
Texas Oncology | San Antonio | Texas | 78258 | United States | Details |